Olaparib para tratamiento de mantenimiento en 2º línea adyuvante de pacientes adultos con Cáncer de Mama Temprano HER2-negativo, de alto riesgo, con mutaciones germinales en BRCA1/2 / Olaparib for adjuvant 2nd-line maintenance treatment of adult patients with high-risk, HER2-negative Early Breast Cancer with germline mutations in BRCA1/2
San Salvador; ISSS; oct. 2023.
Non-conventional
in Spanish
| BRISA/RedTESA
| ID: biblio-1537788
Responsible library:
BR1.1
Subject(s)
Full text:
Available
Collection:
Tematic databases
Database:
BRISA/RedTESA
Main subject:
Breast Neoplasms
/
Genes, erbB-2
/
Genes, BRCA1
/
Genes, BRCA2
/
Poly(ADP-ribose) Polymerase Inhibitors
Type of study:
Health technology assessment
Limits:
Humans
Language:
Spanish
Year:
2023
Document type:
Non-conventional
